DESTINY-Breast03 Phase 3 Study Results
TDD of QLQ-C30 Pain Symptoms
100
80
80
60
60
Time to definitive deterioration, %
T
40
40
20
20
60
LO
T
T
01
2 3
4 5
T
7
8
00
+ Censor
T-DXD (n = 261)
T-DM1 (n = 263)
나가
화가
жи
DESTINY-Breast03
10
Daiichi-Sankyo
Median (95% CI) TDD, months
10.8 (8.3-14.0) HR (95% CI): 0.75 (0.59-0.95)
8.3 (6.6-9.8) P value: 0.0146
T
T
T
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Time, months
Patients at risk:
T-DXD 261 240 210 193 182 168 152 141 129 120 111 100 89 80 68 58 44 31 26 17 14 11 11 6 6 3 1 1 0
T-DM1 263 237 185 169 161 141 118 100 87 67 59 49 34 28 24 20 18 13 11 7 7 4 3 3 0
EORTC, European Organization for Research and Treatment of Cancer; HR, hazard ratio; QLQ-C30, Quality of Life Core 30 questionnaire; TDD, time to definitive deterioration;
T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
P values are not adjusted for multiple testing. TDD is defined as a >10-point change from baseline.
ESMO BC 2022 #1630 Oral
45View entire presentation